Human nature meets technology in MedTech sales

Tern plc

Sales teams are asked to master products that change lives, yet the way they are trained rarely matches the complexity or urgency of the task. The numbers tell a familiar story, long onboarding times, high turnover, and widespread target misses. But beneath the statistics lies a deeper truth: much of what is taught simply does not stick.

The core issue is human nature itself. Our brains are wired to forget what we do not actively apply. Traditional sales education, the manuals, the workshops, the static presentations, leans on outdated methods that assume information can be absorbed through repetition.

The shift now underway is about changing how people learn. Artificial Intelligence, Mixed Reality, and Augmented Reality are converging to create environments where knowledge becomes experience. Instead of reading about a medical device, a sales representative can manipulate it holographically, exploring every function and feature in three dimensions. Instead of rehearsing sales pitches in abstract, they can engage with realistic AI-driven simulations that replicate the tension and unpredictability of real clinical conversations.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Search